The use of the Internet has changed the way health care professionals manage diabetes, with platforms now available allowing patients to upload self-monitoring of blood glucose data and share with their health care provider (1). Previous studies have established the efficacy of Internet blood glucose monitoring systems (13).

It is now our standard of care to offer an Internet blood glucose monitoring system to patients. We currently have 1,100 patients enrolled and have outcome data on the first 409 patients. Of the 409 patients, 388 had HbA1c at baseline and at least one subsequent HbA1c determination within 9 months. HbA1c values from 3–9 months were averaged to generate follow-up data. The relationship of reporting frequency and HbA1c change was determined by dividing patients into frequent reporters, who reported more than once per month, and infrequent reporters.

Patients were instructed to upload self-monitoring of blood glucose readings every 2 weeks through their choice of platform including CareLink (Medtronic), meters equipped with report-generating software (Contour USB, Bayer; FreeStyle InsuLinx, Abbott; iBGStar, Sanofi), and a customized spreadsheet (Excel, Microsoft). All platforms generated reports presenting the mean, SD, and range of glucose values according to time of day. The patient’s endocrinologist reviewed the readings and sent feedback to the patient via e-mail. Recommendations included changes in therapy, testing frequency, and lifestyle or encouragement to continue with no changes.

Key results are summarized in Table 1.

Table 1

Baseline and follow-up HbA1c in frequent and infrequent reporting patients

Baseline and follow-up HbA1c in frequent and infrequent reporting patients
Baseline and follow-up HbA1c in frequent and infrequent reporting patients

HbA1c in all type 2 diabetic patients declined from 8.36 ± 1.35% to 7.91 ± 0.98% (P < 0.001). For type 2 diabetic patients treated with insulin, HbA1c declined from 8.53 ± 0.82 to 8.12 ± 0.91% (P < 0.001). Type 2 diabetic patients exclusively on oral hypoglycemic agents (OHAs) declined from 8.15 ± 0.98 to 7.67 ± 1.29% (P < 0.001).

At baseline for type 2 diabetic patients, there was no statistically significant difference in HbA1c values for the groups whether they were frequent or infrequent reporters. At follow-up, it was found that HbA1c in frequent reporters were significantly lower than in infrequent reporters, regardless of treatment (P < 0.05).

It was found that type 1 diabetic patients who had “ideal” HbA1c showed little decrement in HbA1c values. When excluding patients with HbA1c <6.9 (n = 17), type 1 diabetic patients showed a decline of 8.12 ± 1.38% to 7.93 ± 1.17% (P < 0.01).

We observed a trend of less frequent reporting among type 1 diabetic patients with lower HbA1c values. When we excluded patients with HbA1c <7.4 (n = 26), we found frequent reporters had lower follow-up HbA1c than infrequent reporters (P < 0.05).

Regardless of type of diabetes or treatment, all patients improved significantly. Additionally, when separated into frequent versus infrequent reporters, we found no differences at baseline. At follow-up, frequent reporters had consistently lower HbA1c values.

Previously, there has been a lack of data to fully demonstrate the efficacy of Internet interventions on type 1 diabetic patients, with most available studies conducted on much smaller sample sizes (4,5). We found Internet intervention to be effective across all groups, including type 1 diabetic patients. The lowering of HbA1c improves long-term diabetes outcome and lowers costs. The efficacy of this intervention warrants consideration of coverage for this service by insurance plans.

Funding. This work was supported by the Endocrine Research Society, Vancouver, British Columbia, Canada.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. H.D.T. designed the study, developed the protocol, collected and interpreted data, wrote the manuscript, and reviewed and edited the manuscript. M.E.C., J.H.M.C., and A.B.M. collected the data. S.A.R. contributed to study design and protocol development and reviewed and edited the manuscript. A.M.L. and H.G.T. analyzed data, wrote the manuscript, and reviewed and edited the manuscript. A.S.W. contributed to study design and protocol development, interpreted data, and reviewed and edited the manuscript. All authors read and approved the final manuscript. H.D.T. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

1.
Tildesley
HD
,
Mazanderani
AB
,
Ross
SA
.
Effect of Internet therapeutic intervention on A1C levels in patients with type 2 diabetes treated with insulin
.
Diabetes Care
2010
;
33
:
1738
1740
2.
Tildesley
HD
,
Wright
AW
,
Chan
JH
, et al
. A comparison of Internet monitoring with continuous glucose monitoring in insulin requiring type 2 DM. Presented at the 73rd Scientific Sessions of the American Diabetes Association, 22 June
2013
, Chicago, IL
3.
Tildesley
HD
,
Conway
ME
,
Ross
SA
, et al
. Review of the effect of Internet therapeutic intervention in patients with type 1 and type 2 diabetes. Presented at the 73rd Scientific Sessions of the American Diabetes Association, 22 June
2013
, Chicago, IL
4.
Health Quality Ontario
.
Home telemonitoring for type 2 diabetes: an evidence-based analysis
.
Ont Health Technol Assess Ser
2009
;
9
:
1
38
5.
McCarrier
KP
,
Ralston
JD
,
Hirsch
IB
, et al
.
Web-based collaborative care for type 1 diabetes: a pilot randomized trial
.
Diabetes Technol Ther
2009
;
11
:
211
217
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.